Protein Biomarker Panel for Early AKI Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting acute kidney injury (AKI) following interventional procedures are inadequate, particularly in patients with co-morbidities such as diabetes and heart failure, as serum creatinine and eGFR measures provide only modest accuracy, leading to increased health care costs and mortality.
Innovation Solution
A panel of protein markers, including CD5 antigen-like, C-reactive protein, Factor VII, kidney injury molecule 1, N-terminal prohormone of brain natriuretic peptide, and osteopontin, along with clinical variables like blood urea nitrogen creatinine ratio and history of diabetes mellitus type 2, are used to determine AKI risk through an analytical device, calculating a prognostic score for early detection and intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serum creatinine and eGFR measures are used to predict AKI risk, then the diagnostic method is simple and widely available, but the prediction accuracy is only modest
Solution Approach 1:
The patent combines multiple protein markers (including cystatin C, beta-2 microglobulin, and other renal-specific proteins) with traditional serum creatinine and eGFR measures into a composite diagnostic panel. This merging of multiple biomarkers enhances AKI risk prediction accuracy beyond what any single marker can provide, while maintaining clinical utility through standardized testing protocols
2Reliability
If standard kidney function measures are used, then the monitoring method is straightforward, but the ability to accurately predict incident AKI is limited
Solution Approach 1:
The patent enables preliminary detection of AKI risk by measuring protein marker levels before contrast imaging procedures or other nephrotoxic exposures. This preliminary action allows for pre-procedural risk stratification and preventive interventions, improving reliability of incident AKI prediction by catching at-risk patients before actual injury occurs
Solution Approach 2:
The diagnostic panel serves multiple functions: it predicts incident AKI risk before procedures, monitors ongoing kidney function, and provides prognostic information for patients with co-morbidities. This multi-functionality enhances reliability across different clinical scenarios without requiring separate testing systems
3Measurement precision
If protein marker panels are implemented, then the prediction accuracy improves with AUC of 0.79-0.82, but the assay complexity and cost increase
Solution Approach 1:
The patent optimizes the protein marker panel by selecting specific markers and determining their optimal concentration thresholds for risk stratification. This parameter optimization maintains high prediction accuracy (AUC 0.79-0.82) while reducing the number of markers needed compared to comprehensive proteomic approaches, thereby simplifying assay implementation
Data Source
AI summary
Compositions and methods are provided for diagnosis and/or prognosis of acute kidney injury risk following medical procedures in a subject. In some embodiments, the method includes measuring and comparing the level of particular proteins to other proteins. In other embodiments, the method includes measuring proteins levels with clinical variable information and comparing this composite with the composite of other protein levels with clinical variable information.